MEETING BRIEFS

ASH 2022: Lymphoma

The latest news from ASH 2022: Lymphoma, including features, abstracts, information about the conference, and more.

ASH Lymphoma eBook

Focus on ASH Lymphoma...

Feb 21, 2023

Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score...

Dec 19, 2022

Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...

Dec 16, 2022

PW QUIZ

Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...

Dec 15, 2022

Consolidation high-dose chemotherapy followed by autologous stem cell transplantation...

Dec 15, 2022

In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...

Dec 15, 2022

Friday, December 9th 7:00 a.m.– 6:00 p.m. Registration open (for in-person participants) 7:00...

Dec 6, 2022

Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is...

Dec 6, 2022

The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and...

Dec 6, 2022

EXPLORE MORE

Dec 6, 2022

FSS are industry-supported, CME-certified symposia. These sessions are not part of the official...

Nov 30, 2022

African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience...

Nov 28, 2022

A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...

Nov 28, 2022

For tailored therapy selection and result optimization in diffuse large B-cell lymphoma...